Actelion Stops Tezosentan Trial

The acute heart failure drug has "too remote a chance" of reaching statistically significant efficacy endpoints, an interim analysis by the data safety monitoring board finds. Actelion will wait for a complete analysis of the data before making a further developmental decisions for tezosentan, which would be co-promoted by Genentech.